NCT05063136View on ClinicalTrials.gov

Adjuvant Metronomic Capecitabine Plus Endocrine Therapy for HR+/HER2- Primary Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

1,979

Participants

Timeline

Start Date

September 28, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2028

Conditions
Breast Cancer
Interventions
DRUG

Capecitabine+endocrine therapy

Capecitabine (500mg, tid) (for 1 year)+ standard endocrine therapy (at least 5 years)

DRUG

Placebo+endocrine therapy

Placebo (tid) (for 1 year)+ standard endocrine therapy (at least 5 years)

Trial Locations (1)

Unknown

RECRUITING

Henan cancer hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV